organization · Reporting owner

Venrock Management VI, LLC

Disclosed activity across 2 companies

Tapewire entity: 105876
SEC CIK: 0001495383

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

10x Genomics, Inc.

Report date December 08, 2020 · Filed December 10, 2020

Jointly reported with Venrock Associates VI, L.P., Venrock Partners VI, L.P., Venrock Partners Management VI, LLC

Section 16 reporting ended · disclosed 2020-12-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectBy funds	3,037,825	Reported balance After 2020-12-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-12-08 · Conversion · Acquired 3,000,000 · Balance 3,037,825 F1: Represents shares of Class A Common Stock received upon conversion of 3,000,000 shares of Class B Common Stock. F2: Consists of 2,816,685 shares of Class A Common Stock held by Venrock Associates VI, L.P. ("VA VI") and 221,140 shares of Class A Common Stock held by Venrock Partners VI, L.P. ("VP VI").
Class A Common StockSEC Table I · non-derivative	IndirectBy funds	2,306,517	Reported balance After 2020-12-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-12-08 · Other · Disposed 731,308 · Balance 2,306,517 F3: On December 8, 2020, VA VI and VP VI distributed an aggregate of 1,000,000 shares of Class A Common Stock to their limited partners and general partners. Of the 1,000,000 shares distributed, 249,521 shares were distributed by VA VI to its general partner, Venrock Management VI, LLC ("VM VI") and 19,171 shares were distributed by VP VI to its general partner, Venrock Partners Management VI, LLC ("VPM VI"). F4: Consists of 1,889,497 shares of Class A Common Stock held by VA VI, 249,521 shares of Class A Common Stock held by VM VI, 148,328 shares of Class A Common Stock held by VP VI and 19,171 shares of Class A Common Stock held by VPM VI.
Class A Common StockSEC Table I · non-derivative	IndirectBy funds	2,037,825	Reported balance After 2020-12-10 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-12-10 · Other · Disposed 268,692 · Balance 2,037,825 F5: On December 10, 2020, VM VI and VPM VI distributed an aggregate of 268,692 shares of Class A Common Stock to their members and participants. F6: Consists of 1,889,497 shares of Class A Common Stock held by VA VI and 148,328 shares of Class A Common Stock held by VP VI.
Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectBy funds	5,790,422	Reported balance After 2020-12-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-12-08 · Conversion · Disposed 3,000,000 · Balance 5,790,422 F7: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, all outstanding shares of Class B Common Stock will convert automatically into Class A Common Stock upon any transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F8: Consists of 5,368,880 shares of Class B Common Stock held by VA VI and 421,542 shares of Class B Common Stock held by VP VI.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Class A Common Stock received upon conversion of 3,000,000 shares of Class B Common Stock.

F2: Consists of 2,816,685 shares of Class A Common Stock held by Venrock Associates VI, L.P. ("VA VI") and 221,140 shares of Class A Common Stock held by Venrock Partners VI, L.P. ("VP VI").

F3: On December 8, 2020, VA VI and VP VI distributed an aggregate of 1,000,000 shares of Class A Common Stock to their limited partners and general partners. Of the 1,000,000 shares distributed, 249,521 shares were distributed by VA VI to its general partner, Venrock Management VI, LLC ("VM VI") and 19,171 shares were distributed by VP VI to its general partner, Venrock Partners Management VI, LLC ("VPM VI").

F4: Consists of 1,889,497 shares of Class A Common Stock held by VA VI, 249,521 shares of Class A Common Stock held by VM VI, 148,328 shares of Class A Common Stock held by VP VI and 19,171 shares of Class A Common Stock held by VPM VI.

F5: On December 10, 2020, VM VI and VPM VI distributed an aggregate of 268,692 shares of Class A Common Stock to their members and participants.

F6: Consists of 1,889,497 shares of Class A Common Stock held by VA VI and 148,328 shares of Class A Common Stock held by VP VI.

F7: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, all outstanding shares of Class B Common Stock will convert automatically into Class A Common Stock upon any transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.

F8: Consists of 5,368,880 shares of Class B Common Stock held by VA VI and 421,542 shares of Class B Common Stock held by VP VI.

CASTLIGHT HEALTH, INC.

Report date February 17, 2022 · Filed February 18, 2022

Jointly reported with VENROCK ASSOCIATES V LP, VENROCK PARTNERS V L P, Venrock Entrepreneurs Fund V, L.P., Venrock Management V, LLC, Venrock Partners Management V, LLC, VEF Management V, LLC, Venrock Associates VI, L.P., Venrock Partners VI, L.P., Venrock Partners Management VI, LLC

Section 16 reporting ended · disclosed 2022-02-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Common StockSEC Table I · non-derivative	IndirectBy Funds	0	Reported balance After 2022-02-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-02-17 · Disposition to issuer · Disposed 5,255,264 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 4, 2022, by and among the Issuer, Vera Whole Health, Inc. ("Vera Health"), and Carbon Merger Sub, Inc. (the "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Vera Health, effective as of February 17, 2022 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Issuer's Class A common stock and Class B common stock was exchanged for $2.05 in cash at the Effective Time. F2: Venrock Associates VI, L.P. ("VA6") held an aggregate of 3,707,442 shares of Class B Common Stock, Venrock Partners VI, L.P. ("VP6") held an aggregate of 291,092 shares of Class B Common Stock, Venrock Associates V, L.P. ("VA5") held an aggregate of 1,133,948 shares of Class B Common Stock and 14,047,522 shares of Class A Common Stock, Venrock Partners V, L.P. ("VP5") held an aggregate of 96,139 shares of Class B Common Stock and 1,190,996 shares of Class A Common Stock and Venrock Entrepreneurs Fund V, L.P. ("VEF5") held an aggregate of 26,643 shares of Class B Common Stock and 330,053 shares of Class A Common Stock. F3: Venrock Management VI, LLC, Venrock Partners Management VI, LLC, Venrock Management V, LLC, VEF Management V, LLC and Venrock Partners Management V, LLC (collectively, the "Venrock GP Entities") are the sole general partners of VA6, VP6, VA5, VEF5 and VP5, respectively, and may be deemed to beneficially own these shares. The Venrock GP Entities expressly disclaim beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein.
Class A Common StockSEC Table II · derivative / convertible security	IndirectBy Funds	0	Reported balance After 2022-02-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-02-17 · Disposition to issuer · Disposed 15,568,571 · Balance 0 F4: Each share of Class A Common Stock is convertible at any time at the option of the holder into one (1) share of Class B Common Stock. In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, to any transferee who is not a "Permitted Transferee", as defined in the Issuer's Restated Certificate of Incorporation immediately prior to the Effective Time. The shares of Class A Common Stock have no expiration date. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 4, 2022, by and among the Issuer, Vera Whole Health, Inc. ("Vera Health"), and Carbon Merger Sub, Inc. (the "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Vera Health, effective as of February 17, 2022 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Issuer's Class A common stock and Class B common stock was exchanged for $2.05 in cash at the Effective Time. F5: Each share of Class A Common Stock converted into one (1) share of Class B Common Stock at the Effective Time. F2: Venrock Associates VI, L.P. ("VA6") held an aggregate of 3,707,442 shares of Class B Common Stock, Venrock Partners VI, L.P. ("VP6") held an aggregate of 291,092 shares of Class B Common Stock, Venrock Associates V, L.P. ("VA5") held an aggregate of 1,133,948 shares of Class B Common Stock and 14,047,522 shares of Class A Common Stock, Venrock Partners V, L.P. ("VP5") held an aggregate of 96,139 shares of Class B Common Stock and 1,190,996 shares of Class A Common Stock and Venrock Entrepreneurs Fund V, L.P. ("VEF5") held an aggregate of 26,643 shares of Class B Common Stock and 330,053 shares of Class A Common Stock. F3: Venrock Management VI, LLC, Venrock Partners Management VI, LLC, Venrock Management V, LLC, VEF Management V, LLC and Venrock Partners Management V, LLC (collectively, the "Venrock GP Entities") are the sole general partners of VA6, VP6, VA5, VEF5 and VP5, respectively, and may be deemed to beneficially own these shares. The Venrock GP Entities expressly disclaim beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 4, 2022, by and among the Issuer, Vera Whole Health, Inc. ("Vera Health"), and Carbon Merger Sub, Inc. (the "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Vera Health, effective as of February 17, 2022 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Issuer's Class A common stock and Class B common stock was exchanged for $2.05 in cash at the Effective Time.

F2: Venrock Associates VI, L.P. ("VA6") held an aggregate of 3,707,442 shares of Class B Common Stock, Venrock Partners VI, L.P. ("VP6") held an aggregate of 291,092 shares of Class B Common Stock, Venrock Associates V, L.P. ("VA5") held an aggregate of 1,133,948 shares of Class B Common Stock and 14,047,522 shares of Class A Common Stock, Venrock Partners V, L.P. ("VP5") held an aggregate of 96,139 shares of Class B Common Stock and 1,190,996 shares of Class A Common Stock and Venrock Entrepreneurs Fund V, L.P. ("VEF5") held an aggregate of 26,643 shares of Class B Common Stock and 330,053 shares of Class A Common Stock.

F3: Venrock Management VI, LLC, Venrock Partners Management VI, LLC, Venrock Management V, LLC, VEF Management V, LLC and Venrock Partners Management V, LLC (collectively, the "Venrock GP Entities") are the sole general partners of VA6, VP6, VA5, VEF5 and VP5, respectively, and may be deemed to beneficially own these shares. The Venrock GP Entities expressly disclaim beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein.

F4: Each share of Class A Common Stock is convertible at any time at the option of the holder into one (1) share of Class B Common Stock. In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, to any transferee who is not a "Permitted Transferee", as defined in the Issuer's Restated Certificate of Incorporation immediately prior to the Effective Time. The shares of Class A Common Stock have no expiration date.

F5: Each share of Class A Common Stock converted into one (1) share of Class B Common Stock at the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 17, 2022 Filed Feb 18, 2022 14:13 UTC	CASTLIGHT HEALTH, INC. CSLT · Entity 130187	Disposition to issuerClass A Common Stock · Derivative	15,568,571	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-011152 · doc4.xml · derivative · entry 2 VENROCK ASSOCIATES V LP · CIK 0001391289 · 10% owner VENROCK PARTNERS V L P · CIK 0001395760 · 10% owner Venrock Entrepreneurs Fund V, L.P. · CIK 0001444114 · 10% owner Venrock Management V, LLC · CIK 0001444116 · 10% owner Venrock Partners Management V, LLC · CIK 0001444117 · 10% owner VEF Management V, LLC · CIK 0001444112 · 10% owner Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 0 Underlying: Class B Common Stock · 15,568,571 shares Expires not disclosed F4 · derivative.exercise_price: Each share of Class A Common Stock is convertible at any time at the option of the holder into one (1) share of Class B Common Stock. In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, to any transferee who is not a "Permitted Transferee", as defined in the Issuer's Restated Certificate of Incorporation immediately prior to the Effective Time. The shares of Class A Common Stock have no expiration date. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 4, 2022, by and among the Issuer, Vera Whole Health, Inc. ("Vera Health"), and Carbon Merger Sub, Inc. (the "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Vera Health, effective as of February 17, 2022 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Issuer's Class A common stock and Class B common stock was exchanged for $2.05 in cash at the Effective Time. F4 · derivative.exercise_date: Each share of Class A Common Stock is convertible at any time at the option of the holder into one (1) share of Class B Common Stock. In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, to any transferee who is not a "Permitted Transferee", as defined in the Issuer's Restated Certificate of Incorporation immediately prior to the Effective Time. The shares of Class A Common Stock have no expiration date. F5 · derivative.exercise_date: Each share of Class A Common Stock converted into one (1) share of Class B Common Stock at the Effective Time. F4 · derivative.expiration_date: Each share of Class A Common Stock is convertible at any time at the option of the holder into one (1) share of Class B Common Stock. In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, to any transferee who is not a "Permitted Transferee", as defined in the Issuer's Restated Certificate of Incorporation immediately prior to the Effective Time. The shares of Class A Common Stock have no expiration date. F5 · derivative.expiration_date: Each share of Class A Common Stock converted into one (1) share of Class B Common Stock at the Effective Time. F2 · ownership.nature: Venrock Associates VI, L.P. ("VA6") held an aggregate of 3,707,442 shares of Class B Common Stock, Venrock Partners VI, L.P. ("VP6") held an aggregate of 291,092 shares of Class B Common Stock, Venrock Associates V, L.P. ("VA5") held an aggregate of 1,133,948 shares of Class B Common Stock and 14,047,522 shares of Class A Common Stock, Venrock Partners V, L.P. ("VP5") held an aggregate of 96,139 shares of Class B Common Stock and 1,190,996 shares of Class A Common Stock and Venrock Entrepreneurs Fund V, L.P. ("VEF5") held an aggregate of 26,643 shares of Class B Common Stock and 330,053 shares of Class A Common Stock. F3 · ownership.nature: Venrock Management VI, LLC, Venrock Partners Management VI, LLC, Venrock Management V, LLC, VEF Management V, LLC and Venrock Partners Management V, LLC (collectively, the "Venrock GP Entities") are the sole general partners of VA6, VP6, VA5, VEF5 and VP5, respectively, and may be deemed to beneficially own these shares. The Venrock GP Entities expressly disclaim beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document
February 17, 2022 Filed Feb 18, 2022 14:13 UTC	CASTLIGHT HEALTH, INC. CSLT · Entity 130187	Disposition to issuerClass B Common Stock	5,255,264	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-011152 · doc4.xml · nonDerivative · entry 1 VENROCK ASSOCIATES V LP · CIK 0001391289 · 10% owner VENROCK PARTNERS V L P · CIK 0001395760 · 10% owner Venrock Entrepreneurs Fund V, L.P. · CIK 0001444114 · 10% owner Venrock Management V, LLC · CIK 0001444116 · 10% owner Venrock Partners Management V, LLC · CIK 0001444117 · 10% owner VEF Management V, LLC · CIK 0001444112 · 10% owner Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 4, 2022, by and among the Issuer, Vera Whole Health, Inc. ("Vera Health"), and Carbon Merger Sub, Inc. (the "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Vera Health, effective as of February 17, 2022 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Issuer's Class A common stock and Class B common stock was exchanged for $2.05 in cash at the Effective Time. F2 · ownership.nature: Venrock Associates VI, L.P. ("VA6") held an aggregate of 3,707,442 shares of Class B Common Stock, Venrock Partners VI, L.P. ("VP6") held an aggregate of 291,092 shares of Class B Common Stock, Venrock Associates V, L.P. ("VA5") held an aggregate of 1,133,948 shares of Class B Common Stock and 14,047,522 shares of Class A Common Stock, Venrock Partners V, L.P. ("VP5") held an aggregate of 96,139 shares of Class B Common Stock and 1,190,996 shares of Class A Common Stock and Venrock Entrepreneurs Fund V, L.P. ("VEF5") held an aggregate of 26,643 shares of Class B Common Stock and 330,053 shares of Class A Common Stock. F3 · ownership.nature: Venrock Management VI, LLC, Venrock Partners Management VI, LLC, Venrock Management V, LLC, VEF Management V, LLC and Venrock Partners Management V, LLC (collectively, the "Venrock GP Entities") are the sole general partners of VA6, VP6, VA5, VEF5 and VP5, respectively, and may be deemed to beneficially own these shares. The Venrock GP Entities expressly disclaim beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document
December 10, 2020 Filed Dec 10, 2020 18:13 UTC	10x Genomics, Inc. TXG · Entity 2172	OtherClass A Common Stock	268,692	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062775 · doc4.xml · nonDerivative · entry 3 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 2,037,825 F5 · kind: On December 10, 2020, VM VI and VPM VI distributed an aggregate of 268,692 shares of Class A Common Stock to their members and participants. F5 · shares: On December 10, 2020, VM VI and VPM VI distributed an aggregate of 268,692 shares of Class A Common Stock to their members and participants. F5 · price: On December 10, 2020, VM VI and VPM VI distributed an aggregate of 268,692 shares of Class A Common Stock to their members and participants. F6 · ownership.nature: Consists of 1,889,497 shares of Class A Common Stock held by VA VI and 148,328 shares of Class A Common Stock held by VP VI. Read SEC document
December 08, 2020 Filed Dec 10, 2020 18:13 UTC	10x Genomics, Inc. TXG · Entity 2172	ConversionClass B Common Stock · Derivative	3,000,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-20-062775 · doc4.xml · derivative · entry 4 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 5,790,422 Underlying: Class A Common Stock · 3,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, all outstanding shares of Class B Common Stock will convert automatically into Class A Common Stock upon any transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F7 · derivative.exercise_date: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, all outstanding shares of Class B Common Stock will convert automatically into Class A Common Stock upon any transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F7 · derivative.expiration_date: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, all outstanding shares of Class B Common Stock will convert automatically into Class A Common Stock upon any transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F8 · ownership.nature: Consists of 5,368,880 shares of Class B Common Stock held by VA VI and 421,542 shares of Class B Common Stock held by VP VI. Read SEC document
December 08, 2020 Filed Dec 10, 2020 18:13 UTC	10x Genomics, Inc. TXG · Entity 2172	OtherClass A Common Stock	731,308	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062775 · doc4.xml · nonDerivative · entry 2 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 2,306,517 F3 · kind: On December 8, 2020, VA VI and VP VI distributed an aggregate of 1,000,000 shares of Class A Common Stock to their limited partners and general partners. Of the 1,000,000 shares distributed, 249,521 shares were distributed by VA VI to its general partner, Venrock Management VI, LLC ("VM VI") and 19,171 shares were distributed by VP VI to its general partner, Venrock Partners Management VI, LLC ("VPM VI"). F3 · shares: On December 8, 2020, VA VI and VP VI distributed an aggregate of 1,000,000 shares of Class A Common Stock to their limited partners and general partners. Of the 1,000,000 shares distributed, 249,521 shares were distributed by VA VI to its general partner, Venrock Management VI, LLC ("VM VI") and 19,171 shares were distributed by VP VI to its general partner, Venrock Partners Management VI, LLC ("VPM VI"). F3 · price: On December 8, 2020, VA VI and VP VI distributed an aggregate of 1,000,000 shares of Class A Common Stock to their limited partners and general partners. Of the 1,000,000 shares distributed, 249,521 shares were distributed by VA VI to its general partner, Venrock Management VI, LLC ("VM VI") and 19,171 shares were distributed by VP VI to its general partner, Venrock Partners Management VI, LLC ("VPM VI"). F4 · ownership.nature: Consists of 1,889,497 shares of Class A Common Stock held by VA VI, 249,521 shares of Class A Common Stock held by VM VI, 148,328 shares of Class A Common Stock held by VP VI and 19,171 shares of Class A Common Stock held by VPM VI. Read SEC document
December 08, 2020 Filed Dec 10, 2020 18:13 UTC	10x Genomics, Inc. TXG · Entity 2172	ConversionClass A Common Stock	3,000,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062775 · doc4.xml · nonDerivative · entry 1 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 3,037,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of Class A Common Stock received upon conversion of 3,000,000 shares of Class B Common Stock. F2 · ownership.nature: Consists of 2,816,685 shares of Class A Common Stock held by Venrock Associates VI, L.P. ("VA VI") and 221,140 shares of Class A Common Stock held by Venrock Partners VI, L.P. ("VP VI"). Read SEC document
September 18, 2020 Filed Sep 18, 2020 16:32 UTC	10x Genomics, Inc. TXG · Entity 2172	OtherClass A Common Stock	338,019	$0.00	$0.00	Disclosure SEC source: 0001209191-20-051155 · doc4.xml · nonDerivative · entry 2 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 37,825 F3 · kind: On September 18, 2020, VM VI and VPM VI distributed an aggregate of 338,019 shares of Class A Common Stock to their members and participants pursuant to the Plan. F3 · shares: On September 18, 2020, VM VI and VPM VI distributed an aggregate of 338,019 shares of Class A Common Stock to their members and participants pursuant to the Plan. F4 · ownership.nature: Consists of 35,085 shares of Class A Common Stock held by VA VI and 2,740 shares of Class A Common Stock held by VP VI. Read SEC document
September 16, 2020 Filed Sep 18, 2020 16:32 UTC	10x Genomics, Inc. TXG · Entity 2172	OtherClass A Common Stock	911,981	$0.00	$0.00	Disclosure SEC source: 0001209191-20-051155 · doc4.xml · nonDerivative · entry 1 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 375,844 F1 · kind: On September 16, 2020, Venrock Associates VI, L.P. ("VA VI") and Venrock Partners VI, L.P. ("VP VI") distributed an aggregate of 1,250,000 shares of Class A Common Stock to their limited partners and general partners pursuant to a Trading and Distribution Plan adopted on September 11, 2020 (the "Plan"). Pursuant to the terms of the Plan, of the 1,250,000 shares distributed, 313,898 shares were distributed by VA VI to its general partner, Venrock Management VI, LLC ("VM VI") and 24,121 shares were distributed by VP VI to its general partner, Venrock Partners Management VI, LLC ("VPM VI"). F1 · shares: On September 16, 2020, Venrock Associates VI, L.P. ("VA VI") and Venrock Partners VI, L.P. ("VP VI") distributed an aggregate of 1,250,000 shares of Class A Common Stock to their limited partners and general partners pursuant to a Trading and Distribution Plan adopted on September 11, 2020 (the "Plan"). Pursuant to the terms of the Plan, of the 1,250,000 shares distributed, 313,898 shares were distributed by VA VI to its general partner, Venrock Management VI, LLC ("VM VI") and 24,121 shares were distributed by VP VI to its general partner, Venrock Partners Management VI, LLC ("VPM VI"). F2 · ownership.nature: Consists of 35,085 shares of Class A Common Stock held by VA VI, 2,740 shares of Class A Common Stock held by VP VI, 313,898 shares of Class A Common Stock held by VM VI and 24,121 shares of Class A Common Stock held by VPM VI. Read SEC document
May 20, 2020 Filed May 22, 2020 16:09 UTC	10x Genomics, Inc. TXG · Entity 2172	ConversionClass B Common Stock · Derivative	1,013,569	$0.00	$0.00	Disclosure SEC source: 0001495384-20-000002 · edgar.xml · derivative · entry 3 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 8,790,422 Underlying: Class A Common Stock · 1,013,569 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.underlying: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F2 · ownership.nature: Represents (a) 8,150,480 shares of Class B common stock held by Venrock Associates VI, L.P. ("VA VI") and (b) 639,942 shares of Class B common stock held by Venrock Partners VI, L.P. ("VP VI"). Venrock Management VI, LLC ("VM VI") is the sole general partner of VA VI. Venrock Partners Management VI, LLC ("VPM VI") is the sole general partner of VP VI. VM VI and VPM VI disclaim beneficial ownership over all shares held by VA VI and VP VI, respectively, except to the extent of their indirect pecuniary interests therein. Read SEC document
May 20, 2020 Filed May 22, 2020 16:09 UTC	10x Genomics, Inc. TXG · Entity 2172	SaleClass A Common Stock	1,013,569	$78.00	$79,058,382.00	Disclosure SEC source: 0001495384-20-000002 · edgar.xml · nonDerivative · entry 2 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 1,287,825 F4 · ownership.nature: Represents (a) 1,194,071 shares of Class A common stock held by VA VI and (b) 93,754 shares of Class A common stock held by VP VI. VM VI is the sole general partner of VA VI. VPM VI is the sole general partner of VP VI. VM VI and VPM VI disclaim beneficial ownership over all shares held by VA VI and VP VI, respectively, except to the extent of their indirect pecuniary interests therein. Read SEC document
May 20, 2020 Filed May 22, 2020 16:09 UTC	10x Genomics, Inc. TXG · Entity 2172	ConversionClass A Common Stock	1,013,569	$0.00	$0.00	Disclosure SEC source: 0001495384-20-000002 · edgar.xml · nonDerivative · entry 1 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 2,301,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F3 · ownership.nature: Represents (a) 2,133,852 shares of Class A common stock held by VA VI and (b) 167,542 shares of Class A common stock held by VP VI. VM VI is the sole general partner of VA VI. VPM VI is the sole general partner of VP VI. VM VI and VPM VI disclaim beneficial ownership over all shares held by VA VI and VP VI, respectively, except to the extent of their indirect pecuniary interests therein. Read SEC document
May 01, 2020 Filed May 1, 2020 20:47 UTC	10x Genomics, Inc. TXG · Entity 2172	ConversionClass B Common Stock · Derivative	1,287,825	$0.00	$0.00	Disclosure SEC source: 0001495384-20-000001 · edgar.xml · derivative · entry 2 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 9,803,991 Underlying: Class A Common Stock · 1,287,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.underlying: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F2 · ownership.nature: Represents (a) 9,090,261 shares of Class B common stock held by Venrock Associates VI, L.P. ("VA VI") and (b) 713,730 shares of Class B common stock held by Venrock Partners VI, L.P. ("VP VI"). Venrock Management VI, LLC ("VM VI") is the sole general partner of VA VI. Venrock Partners Management VI, LLC ("VPM VI") is the sole general partner of VP VI. VM VI and VPM VI disclaim beneficial ownership over all shares held by VA VI and VP VI, respectively, except to the extent of their indirect pecuniary interests therein. Read SEC document
May 01, 2020 Filed May 1, 2020 20:47 UTC	10x Genomics, Inc. TXG · Entity 2172	ConversionClass A Common Stock	1,287,825	$0.00	$0.00	Disclosure SEC source: 0001495384-20-000001 · edgar.xml · nonDerivative · entry 1 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 1,287,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F3 · ownership.nature: Represents (a) 1,194,071 shares of Class A common stock held by VA VI and (b) 93,754 shares of Class A common stock held by VP VI. VM VI is the sole general partner of VA VI. VPM VI is the sole general partner of VP VI. VM VI and VPM VI disclaim beneficial ownership over all shares held by VA VI and VP VI, respectively, except to the extent of their indirect pecuniary interests therein. Read SEC document
September 16, 2019 Filed Sep 16, 2019 17:28 UTC	10x Genomics, Inc. TXG · Entity 2172	ConversionClass B Common Stock · Derivative	11,091,816	$0.00	$0.00	Disclosure SEC source: 0001495384-19-000002 · edgar.xml · derivative · entry 3 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 11,091,816 Underlying: Class A Common Stock · 11,091,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.underlying: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F2 · ownership.nature: Represents (a) 7,250,375 shares of Class B common stock held by Venrock Associates VI, L.P. ("VA VI") and (b) 569,270 shares of Class B common stock held by Venrock Partners VI, L.P. ("VP VI"). Venrock Management VI, LLC ("VM VI"), is the sole general partner of VA VI. Venrock Partners Management VI, LLC ("VPM VI"), is the sole general partner of VP VI. Dr. Roberts is a member of VM VI and VPM VI and disclaims beneficial ownership over all shares held by VA VI and VP VI, except to the extent of his indirect pecuniary interests therein. F3 · ownership.nature: Represents (a) 3,033,957 shares of Class B common stock held by VA VI and (b) 238,214 shares of Class B common stock held by VP VI. VM VI is the sole general partner of VA VI. VPM VI is the sole general partner of VP VI. Dr. Roberts is a member of VM VI and VPM VI and disclaims beneficial ownership over all shares held by VA VI and VP VI, except to the extent of his indirect pecuniary interests therein. Read SEC document
September 16, 2019 Filed Sep 16, 2019 17:28 UTC	10x Genomics, Inc. TXG · Entity 2172	ConversionSeries B Preferred Stock · Derivative	3,272,171	$0.00	$0.00	Disclosure SEC source: 0001495384-19-000002 · edgar.xml · derivative · entry 2 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 0 Underlying: Class B Common Stock · 3,272,171 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.underlying: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F3 · ownership.nature: Represents (a) 3,033,957 shares of Class B common stock held by VA VI and (b) 238,214 shares of Class B common stock held by VP VI. VM VI is the sole general partner of VA VI. VPM VI is the sole general partner of VP VI. Dr. Roberts is a member of VM VI and VPM VI and disclaims beneficial ownership over all shares held by VA VI and VP VI, except to the extent of his indirect pecuniary interests therein. Read SEC document
September 16, 2019 Filed Sep 16, 2019 17:28 UTC	10x Genomics, Inc. TXG · Entity 2172	ConversionSeries A-2 Preferred Stock · Derivative	7,819,645	$0.00	$0.00	Disclosure SEC source: 0001495384-19-000002 · edgar.xml · derivative · entry 1 Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 0 Underlying: Class B Common Stock · 7,819,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.underlying: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering and had no expiration date. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F2 · ownership.nature: Represents (a) 7,250,375 shares of Class B common stock held by Venrock Associates VI, L.P. ("VA VI") and (b) 569,270 shares of Class B common stock held by Venrock Partners VI, L.P. ("VP VI"). Venrock Management VI, LLC ("VM VI"), is the sole general partner of VA VI. Venrock Partners Management VI, LLC ("VPM VI"), is the sole general partner of VP VI. Dr. Roberts is a member of VM VI and VPM VI and disclaims beneficial ownership over all shares held by VA VI and VP VI, except to the extent of his indirect pecuniary interests therein. Read SEC document
April 03, 2017 Filed Apr 5, 2017 19:07 UTC	CASTLIGHT HEALTH, INC. CSLT · Entity 130187	GrantClass B Common Stock	3,965,979	Not disclosed	Not disclosed	Disclosure SEC source: 0001391289-17-000001 · edgar.xml · nonDerivative · entry 1 VENROCK ASSOCIATES V LP · CIK 0001391289 · 10% owner VENROCK PARTNERS V L P · CIK 0001395760 · 10% owner Venrock Entrepreneurs Fund V, L.P. · CIK 0001444114 · 10% owner Venrock Management V, LLC · CIK 0001444116 · 10% owner Venrock Partners Management V, LLC · CIK 0001444117 · 10% owner VEF Management V, LLC · CIK 0001444112 · 10% owner Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 5,222,709 F1 · price: Received in exchange for 6,026,800 shares of Series B Preferred Stock of Jiff, Inc. ("Jiff") held by Venrock Associates VI, L.P. ("VA6"), 473,200 shares of Jiff's Series B Preferred Stock held by Venrock Partners VI, L.P. ("VP6"), 1,428,732 shares of Jiff's Series C Preferred Stock held by VA6, and 112,178 shares of Jiff's Series C Preferred Stock held by VP6 pursuant to the Agreement and Plan of Merger and Reorganization dated as of January 4, 2017 (the "Merger Agreement") by and among the Issuer, Neptune Acquisition Subsidiary, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), Jiff and Fortis Advisors LLC, as the Stockholders' Agent ("Stockholders' Agent"). Pursuant to the Merger Agreement, on April 3, 2017 (the "Effective Time"), Merger Sub merged with and into Jiff with Jiff surviving the merger as a wholly owned subsidiary of Issuer (the "Merger"). At the Effective Time, the closing price of the Issuer's Class B Common Stock was $3.65 per share. F2 · price: Of the 3,965,979 shares issued as reported herein, 401,779 shares and 31,546 shares held by VA6 and VP6, respectively, are currently being held in escrow for 12-months following the Merger to serve as partial security for certain indemnification obligations of Jiff stockholders pursuant to the Merger Agreement and 7,441 shares and 584 shares held by VA6 and VP6, respectively, are being held in an expense fund, which will be used for the purposes of paying directly or reimbursing the Stockholders' Agent for out-of-pocket costs and expenses and legal fees incurred by the Stockholders' Agent in connection with the administration of its duties. F3 · balance_after: The Merger Agreement provides that the former equityholders of Jiff (other than the holders of Jiff's Series A Preferred Stock) will receive additional shares of the Issuer's Class B Common Stock upon the achievement by the Jiff business of certain milestones in FY2017. Such former equityholders of Jiff will receive additional shares of the Issuer's Class B Common Stock if the Jiff business achieves at least $25 million in revenue in FY2017 and if the Jiff business achieves at least $25 million in net new bookings during FY2017, and such right to receive additional shares subject to this earn-out right became fixed and irrevocable at the Effective Time. For more information on the earnout, please refer to the Merger Agreement filed as Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on January 4, 2017. F4 · ownership.nature: VA6 holds an aggregate of 3,677,257 shares, VP6 holds an aggregate of 288,722 shares, Venrock Associates V, L.P. ("VA5") holds an aggregate of 1,133,948 shares, Venrock Partners V, L.P. ("VP5") holds an aggregate of 96,139 shares and Venrock Entrepreneurs Fund V, L.P. ("VEF5") holds an aggregate of 26,643 shares. Venrock Management VI, LLC, Venrock Partners Management VI, LLC, Venrock Management V, LLC, VEF Management V, LLC and Venrock Partners Management V, LLC (collectively, the "Venrock GP Entities") are the sole general partners of VA6, VP6, VA5, VEF5 and VP5 (collectively, the "Funds"), respectively, and may be deemed to beneficially own these shares. The Venrock GP Entities expressly disclaim beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document
April 03, 2017 Filed Jun 7, 2019 17:09 UTC Amendment	CASTLIGHT HEALTH, INC. CSLT · Entity 130187	GrantClass B Common Stock	3,998,534	Not disclosed	Not disclosed	Disclosure SEC source: 0001391289-19-000001 · edgar.xml · nonDerivative · entry 1 VENROCK ASSOCIATES V LP · CIK 0001391289 · 10% owner VENROCK PARTNERS V L P · CIK 0001395760 · 10% owner Venrock Entrepreneurs Fund V, L.P. · CIK 0001444114 · 10% owner Venrock Management V, LLC · CIK 0001444116 · 10% owner Venrock Partners Management V, LLC · CIK 0001444117 · 10% owner VEF Management V, LLC · CIK 0001444112 · 10% owner Venrock Associates VI, L.P. · CIK 0001495384 · 10% owner Venrock Partners VI, L.P. · CIK 0001495386 · 10% owner Venrock Management VI, LLC · CIK 0001495383 · 10% owner Venrock Partners Management VI, LLC · CIK 0001495385 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 5,255,264 F1 · price: Received in exchange for 6,026,800 shares of Series B Preferred Stock of Jiff, Inc. ("Jiff") held by Venrock Associates VI, L.P. ("VA6"), 473,200 shares of Jiff's Series B Preferred Stock held by Venrock Partners VI, L.P. ("VP6"), 1,428,732 shares of Jiff's Series C Preferred Stock held by VA6, and 112,178 shares of Jiff's Series C Preferred Stock held by VP6 pursuant to the Agreement and Plan of Merger and Reorganization dated as of January 4, 2017 (the "Merger Agreement") by and among the Issuer, Neptune Acquisition Subsidiary, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), Jiff and Fortis Advisors LLC, as the Stockholders' Agent ("Stockholders' Agent"). Pursuant to the Merger Agreement, on April 3, 2017 (the "Effective Time"), Merger Sub merged with and into Jiff with Jiff surviving the merger as a wholly owned subsidiary of Issuer (the "Merger"). At the Effective Time, the closing price of the Issuer's Class B Common Stock was $3.65 per share. F2 · price: Of the 3,998,534 shares issued as reported herein, 401,779 shares and 31,546 shares held by VA6 and VP6, respectively, are currently being held in escrow for 12-months following the Merger to serve as partial security for certain indemnification obligations of Jiff stockholders pursuant to the Merger Agreement and 7,441 shares and 584 shares held by VA6 and VP6, respectively, are being held in an expense fund, which will be used for the purposes of paying directly or reimbursing the Stockholders' Agent for out-of-pocket costs and expenses and legal fees incurred by the Stockholders' Agent in connection with the administration of its duties. F3 · balance_after: The Merger Agreement provides that the former equityholders of Jiff (other than the holders of Jiff's Series A Preferred Stock) will receive additional shares of the Issuer's Class B Common Stock upon the achievement by the Jiff business of certain milestones in FY2017. Such former equityholders of Jiff will receive additional shares of the Issuer's Class B Common Stock if the Jiff business achieves at least $25 million in revenue in FY2017 and if the Jiff business achieves at least $25 million in net new bookings during FY2017, and such right to receive additional shares subject to this earn-out right became fixed and irrevocable at the Effective Time. For more information on the earnout, please refer to the Merger Agreement filed as Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on January 4, 2017. F4 · ownership.nature: VA6 holds an aggregate of 3,707,442 shares, VP6 holds an aggregate of 291,092 shares, Venrock Associates V, L.P. ("VA5") holds an aggregate of 1,133,948 shares, Venrock Partners V, L.P. ("VP5") holds an aggregate of 96,139 shares and Venrock Entrepreneurs Fund V, L.P. ("VEF5") holds an aggregate of 26,643 shares. Venrock Management VI, LLC, Venrock Partners Management VI, LLC, Venrock Management V, LLC, VEF Management V, LLC and Venrock Partners Management V, LLC (collectively, the "Venrock GP Entities") are the sole general partners of VA6, VP6, VA5, VEF5 and VP5 (collectively, the "Funds"), respectively, and may be deemed to beneficially own these shares. The Venrock GP Entities expressly disclaim beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.